Tilray Brands Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tilray Brands (TLRY) is scheduled to release Q1 earnings on October 9, with analysts forecasting a wider loss of 2 cents per share on projected revenue of $204.55 million, a modest increase year-over-year. The company recently expanded its medical cannabis portfolio in Germany. Shares closed down 2.5% at $1.58 on Monday, against a backdrop of mixed analyst sentiment including a Jefferies 'Buy' rating with a $2 price target, and 'Neutral' ratings from Zelman & Assoc and Piper Sandler, the latter having cut its price target to $1.

Analysis

Tilray Brands, Inc. (NASDAQ:TLRY) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 9. Analysts expect the Leamington, Canada-based company to report a quarterly loss at 2 cents per share, versus a year-ago loss of 1 cent per share. Tilray Brands projects quarterly revenue of $204.55 million, compared to $200.04 million a year earlier, according to data from Benzinga Pro. On Aug. 28, Tilray Brands' medical division expanded its portfolio in Germany with three newly certified cannabis strains. Shares of Tilray Brands fell 2.5% to close at $1.58 on Monday. Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. - Jefferies analyst Kaumil Gajrawala maintained a Buy rating and raised the price target from $1.5 to $2 on Aug. 25, 2025. This analyst has an accuracy rate of 50%. - Zelman & Assoc analyst Pablo Zuanic reiterated a Neutral rating on July 29, 2025. This analyst has an accuracy rate of 52%. - Piper Sandler analyst Michael Lavery maintained a Neutral rating and cut the price target from $2 to $1 on April 9, 2025. This analyst has an accuracy rate of 65%. Considering buying TLRY stock? Here’s what analysts think: Read This Next: Photo via Shutterstock © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Tilray Brands (TLRY) is scheduled to release its Q1 earnings on October 9, with analyst consensus anticipating a widening quarterly loss of 2 cents per share, up from a 1 cent loss year-over-year. Revenue is projected to see a modest increase to $204.55 million, compared to $200.04 million in the previous year, suggesting continued top-line growth challenges despite market expansion efforts. The company recently expanded its medical cannabis portfolio in Germany, a strategic move aimed at growth in the European market. However, TLRY shares closed down 2.5% at $1.58 on Monday, reflecting potential investor apprehension ahead of the upcoming earnings report. Analyst sentiment remains highly mixed, with Jefferies maintaining a "Buy" rating and raising its price target to $2, while Piper Sandler, with a higher accuracy rate of 65%, maintains a "Neutral" rating and recently cut its price target to $1. This divergence in expert opinion and price targets underscores significant uncertainty surrounding Tilray's short-term financial performance and valuation.

Key Decisions for Investors

• Closely monitor Tilray's Q1 earnings report for actual revenue growth and margin trends, especially given the forecasted widening loss and modest revenue increase.
• Evaluate the effectiveness and future contribution of the recent German medical cannabis expansion as a potential driver for long-term top-line growth.
• Acknowledge the significant analyst price target disparity ($1 to $2) and the pre-earnings share depreciation as indicators of heightened market uncertainty and potential volatility.